One study performed a retrospective analysis of bazedoxifene, an inhibitor of the IL-6/IL-6R/GP130 complex, in patients with pancreatic (n = 5) or gastric adenocarcinoma (n = 2), showing biological tumor marker reduction in 80% and disease regression on PET-CT in 60% of cases [51]. This evidence concerns the gene IL6 and gastric adenocarcinoma.